Literature DB >> 3720467

Frequency and significance of antimitochondrial antibodies in severe chronic active hepatitis.

R P Kenny, A J Czaja, J Ludwig, E R Dickson.   

Abstract

Of 187 patients with severe chronic active hepatitis, 37 (20%) had antimitochondrial antibodies, usually of low titer (less than or equal to 1:40). To assess the significance of this finding and to identify differentiating features from primary biliary cirrhosis, 24 of these patients were compared to two groups of matched counterparts of which one lacked antimitochondrial antibodies and one had the antibodies together with typical primary biliary cirrhosis. Higher serum levels of alkaline phosphatase and an increased frequency of stainable hepatic copper were the only features that distinguished these patients from those without antimitochondrial antibodies. The response to corticosteroids was not influenced by antibody status. Histologic interpretation differentiated primary biliary cirrhosis from antibody-positive chronic active hepatitis in 91% of instances. High antibody levels (greater than or equal to 1:160), immunoglobulin M concentrations (greater than or equal to 6.0 mg/ml), alkaline phosphatase activity (greater than or equal to fourfold normal), and cholesterol elevations (greater than or equal to 300 mg/dl) separated the syndromes in 82% of instances. Patients with laboratory features of primary biliary cirrhosis but histologic findings of chronic active hepatitis responded to corticosteroids. We conclude that low titers of antimitochondrial antibodies are common in chronic active hepatitis, and the presence of these antibodies does not preclude a satisfactory response to corticosteroids. Histologic features are more reliable than biochemical findings in differentiating the syndromes and should be the basis for diagnosis and treatment.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3720467     DOI: 10.1007/bf01296447

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  22 in total

1.  Numerical taxonomic analysis of cirrhosis. II. Clinical significance of classifications.

Authors:  P Winkel; N Tygstrup
Journal:  Comput Biomed Res       Date:  1974-04

2.  The occurrence and significance of abnormal bile duct epithelium in chronic aggressive hepatitis. A comparative morphological biochemical, immunological, and prognostic study.

Authors:  P Christoffersen; O Dietrichson; V Faber; H Poulsen
Journal:  Acta Pathol Microbiol Scand A       Date:  1972

3.  Serological diagnosis of primary biliary cirrhosis: a potential clue to pathogenesis.

Authors:  F S Kantor; G Klatskin
Journal:  Trans Assoc Am Physicians       Date:  1967

Review 4.  "Autoallergic" hepatitis.

Authors:  D Doniach; J G Walker; I M Roitt; P A Berg
Journal:  N Engl J Med       Date:  1970-01-08       Impact factor: 91.245

Review 5.  Nonsuppurative destructive chronic cholangitis and chronic hepatitis.

Authors:  H Popper; F Schaffner
Journal:  Prog Liver Dis       Date:  1970

6.  Cholestasis in active chronic hepatitis.

Authors:  W G Cooksley; L W Powell; J F Kerr; P S Bhathal
Journal:  Am J Dig Dis       Date:  1972-06

7.  Observer error and sampling variability tested in evaluation of hepatitis and cirrhosis by liver biopsy.

Authors:  R D Soloway; A H Baggenstoss; L J Schoenfield; W H Summerskill
Journal:  Am J Dig Dis       Date:  1971-12

8.  Serological classification of chronic cholestatic liver disease by the use of two different types of antimitochondrial antibodies.

Authors:  P A Berg; K H Wiedmann; T Sayers; G Klöppel; H Lindner
Journal:  Lancet       Date:  1980 Dec 20-27       Impact factor: 79.321

9.  Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared.

Authors:  W H Summerskill; M G Korman; H V Ammon; A H Baggenstoss
Journal:  Gut       Date:  1975-11       Impact factor: 23.059

10.  Responses to treatment can differentiate chronic active liver disease with cholangitic features from the primary biliary cirrhosis syndrome.

Authors:  A P Geubel; A H Baggenstoss; W H Summerskill
Journal:  Gastroenterology       Date:  1976-09       Impact factor: 22.682

View more
  23 in total

Review 1.  Autoimmune hepatitis and its variant syndromes.

Authors:  Z Ben-Ari; A J Czaja
Journal:  Gut       Date:  2001-10       Impact factor: 23.059

Review 2.  Variant forms of autoimmune hepatitis.

Authors:  A J Czaja
Journal:  Curr Gastroenterol Rep       Date:  1999 Feb-Mar

3.  Detection of liver kidney microsomal type 1 antibody using molecularly based immunoassays.

Authors:  N Kerkar; Y Ma; E T Davies; P Cheeseman; G Mieli-Vergani; D Vergani
Journal:  J Clin Pathol       Date:  2002-12       Impact factor: 3.411

Review 4.  Autoantibody-negative autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2011-12-21       Impact factor: 3.199

Review 5.  Autoimmune hepatitis. Evolving concepts and treatment strategies.

Authors:  A J Czaja
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

Review 6.  Difficult treatment decisions in autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  World J Gastroenterol       Date:  2010-02-28       Impact factor: 5.742

Review 7.  Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment.

Authors:  Albert J Czaja; Yusuf Bayraktar
Journal:  World J Gastroenterol       Date:  2009-05-21       Impact factor: 5.742

Review 8.  Diagnosis and management of the overlap syndromes of autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Can J Gastroenterol       Date:  2013-07       Impact factor: 3.522

Review 9.  The overlap syndromes of autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-08-24       Impact factor: 3.199

Review 10.  Overlap syndromes of autoimmune hepatitis: what is known so far.

Authors:  Marilena Durazzo; Alberto Premoli; Sharmila Fagoonee; Rinaldo Pellicano
Journal:  Dig Dis Sci       Date:  2003-03       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.